Anhydrous alendronate monosodium salt formulations
US5849726A · kind A · utility
18Cited by
3References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 3, 1997 |
| Grant date | Dec 15, 1998 |
| Priority date | — |
| Expiry date | Dec 3, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/3873
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of anhydrous alendronate sodium. Also described is a pharmaceutical dosage form of said anhydrous alendronate sodium, being anhydrous 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, monosodium salt, in a pharmaceutically acceptable excipient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.